Endometrial Clinical Trials

343 recruitingLast updated: July 25, 2026

There are 343 actively recruiting endometrial clinical trials across 54 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Endometrial Trials at a Glance

343 actively recruiting trials for endometrial are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Phase 2 with 110 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running endometrial studies include AstraZeneca, Mayo Clinic, and National Cancer Institute (NCI).

Browse endometrial trials by phase

Treatments under study

About Endometrial Clinical Trials

Looking for clinical trials for Endometrial? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Endometrial trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Endometrial clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 343 trials

Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled409 locationsNCT05256225
Recruiting
Phase 1

DBC-664 in Adult Patients With Solid Tumors

Urothelial CarcinomaLung AdenocarcinomaOvarian Adenocarcinoma+3 more
Duboce Biopharmaceuticals, Inc.210 enrolled3 locationsNCT07705035
Recruiting
Phase 1Phase 2

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Ovarian CancerEndometrial CancerLung Adenocarcinoma+1 more
AstraZeneca602 enrolled60 locationsNCT05797168
Recruiting
Phase 1

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Colorectal, CancerGastric CancerEndometrial Cancer+4 more
MOMA Therapeutics132 enrolled15 locationsNCT06974110
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled483 locationsNCT05564377
Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled18 locationsNCT07124000
Recruiting
Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 1Phase 2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.619 enrolled33 locationsNCT05919264
Recruiting
Phase 1Phase 2

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Endometrial CancerRecurrent Ovarian CancerLow Grade Serous Ovarian Cancer+3 more
Regeneron Pharmaceuticals890 enrolled52 locationsNCT03564340
Recruiting
Phase 1

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Breast CancerOvarian CancerCervical Cancer+6 more
Regor Pharmaceuticals Inc.63 enrolled5 locationsNCT07524322
Recruiting

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

Endometrial CancerEndometrioid AdenocarcinomaEndometrial Cancer Stage I
Memorial Sloan Kettering Cancer Center1,715 enrolled18 locationsNCT04291612
Recruiting
Phase 1

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Gastric CancerEndometrial CancerHepatocellular Carcinoma+5 more
Seagen, a wholly owned subsidiary of Pfizer714 enrolled62 locationsNCT05208762
Recruiting
Phase 1

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 3

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Endometrial Cancer
BioNTech SE480 enrolled171 locationsNCT06340568
Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsStomach NeoplasmsColorectal Neoplasms+4 more
Eli Lilly and Company421 enrolled31 locationsNCT07114601
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled6 locationsNCT07419841
Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled261 locationsNCT06952504
Recruiting
Phase 1

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Phase 2

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
Jonsson Comprehensive Cancer Center32 enrolled1 locationNCT04469764
Recruiting
Not Applicable

Low-Residue Diet Versus Rectal Enema Before Laparoscopic Surgery for Endometrial Cancer

Endometrial Cancer
Mahmut Yassa100 enrolled1 locationNCT07702799